Journal of Hepatology
Volume 54, Issue 1 , Pages 108-114 , January 2011

Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting

  • Caroline Tournoux-Facon

      Affiliations

    • Unité d’Epidémiologie et Biostatistique, Inserm CIC P802, CHU Poitiers, Université de Poitiers, France
    • ,
  • Xavier Paoletti

      Affiliations

    • Service de Biostatistique, Institut Curie, Paris, France
    • INSERM U900, Paris, France
    • Corresponding Author InformationCorresponding author at: Service de Biostatistique, Institut Curie, Paris, France. Tel.: +33 1 56 24 56 47; fax: +33 1 53 10 40 20.
    • ,
  • Jean-Claude Barbare

      Affiliations

    • Délégation à la Recherche Clinique et à l’Innovation, CHU Amiens, France
    • ,
  • Olivier Bouché

      Affiliations

    • Service d’Hépatogastroentérologie, CHU Reims, France
    • ,
  • Philippe Rougier

      Affiliations

    • Hépato-gastro-entérologie, oncologie digestive, Hôpital Ambroise Paré, Boulogne, France
    • ,
  • Laetitia Dahan

      Affiliations

    • Service d’Hépatogastroentérologie et Oncologie Digestive, CHRU AP-HM La Timone, Université de la Méditerranée, Marseille, France
    • ,
  • Catherine Lombard-Bohas

      Affiliations

    • Service d’Hépatogastroentérologie, CHRU Lyon, France
    • ,
  • Roger Faroux

      Affiliations

    • Service d’Hépatogastroentérologie, CH La Roche sur Yon, France
    • ,
  • Jean Luc Raoul

      Affiliations

    • Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, European University in Brittany, France
    • ,
  • Laurent Bedenne

      Affiliations

    • FFCD, INSERM U-866, Dijon, France
    • ,
  • Franck Bonnetain

      Affiliations

    • Unité de biostatistiques et de méthodologie, FFCD, INSERM U-866, Dijon, France

Received 21 September 2009 ,Revised 2 June 2010 ,Accepted 18 June 2010.

References 

  1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928
  2. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751–55.
  3. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001;34:529–534
  4. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840–45.
  5. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338
  6. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’etude et de traitement du carcinome hepatocellulaire. J Hepatol. 1999;31:133–141
  7. Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee HS, et al. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol. 2005;20:765–771
  8. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002;50:881–885
  9. Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg. 2004;91:400–408
  10. Pepe M. the statistical evaluation of medical tests for classification and prediction. Oxford Statistical University 2003.
  11. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL, et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol. 2008;19:1117–1126
  12. Barbare JC, Bouche O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer. 2009;45:1788–1797
  13. Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005;23:4338–4346
  14. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  15. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747–1753
  16. Schemper M. Predictive accuracy and explained variation. Stat Med. 2003;22:2299–2308
  17. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med. 2004;23:723–748
  18. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387
  19. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723–731
  20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. NEJM. 2008;359(4):378–390
  21. HAS/Service des recommandations professionnelles – service évaluation médico-économique et santé publique Septembre 2007.
  22. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009;20:vii1–vii6.
  23. Borie F, Tretarre B, Bouvier AM, Faivre J, Binder F, Launoy G, et al. Primitive liver cancers: epidemiology and geographical study in France. Eur J Gastroenterol Hepatol. 2009;21:984–989
  24. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2003;19:243–249
  25. Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121:525–531
  26. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini MC, Di Nolfo MA, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102:1022–1031
  27. Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouche O, Raoul JL, et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res. 2008;17:831–843

PII: S0168-8278(10)00705-1

doi: 10.1016/j.jhep.2010.06.015

Journal of Hepatology
Volume 54, Issue 1 , Pages 108-114 , January 2011

Article Tools

* Image Usage & Resolution